Antriabio’s basal insulin dream takes flight
By Michael Fitzhugh
Monday, April 28, 2014
Seven big trailers owned by Antriabio Inc. sit parked in Boulder, Colo., holding the keys to a dream deferred: Inside is the equipment PR Pharmaceuticals Inc. (PRP) once used to manufacture microparticles for its experimental sustained-release formulation of basal insulin, Insular. Outside are the rough realities that drove it into Chapter 11 bankruptcy in 2008.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.